ICAAC 2015: Merck's Bezlotoxumab A 'Big Step' In C Diff

Merck & Co.'s bezlotoxumab for the treatment of recurrent clostridium difficile (C diff) infections is "a big step" for treatment of the debilitating and potentially deadly gut infection, according to Dale Gerding, a professor at Loyola University Chicago Stritch School of Medicine and a lead investigator for the monoclonal antibody's Phase III clinical trials.

Merck & Co.'s bezlotoxumab for the treatment of recurrent clostridium difficile (C diff) infections is "a big step" for treatment of the debilitating and potentially deadly gut infection, according to Dale Gerding, a professor at Loyola University Chicago Stritch School of Medicine and a lead investigator for the monoclonal antibody's Phase III clinical trials.

Bezlotoxumab and Merck's actoxumab are the only antibody therapies in clinical development for C diff infections, which are characterized by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapy Areas